The FDA’s recent Prescription Drug Use-Related Software (PDURS) guidance has the potential to transform both the patient and provider experience by integrating digital tools directly with prescription therapies. This advancement allows software to enhance medication use through support for side effect management, adherence, and overall patient engagement, representing a significant step forward in personalized care. For a deeper look into how this guidance could impact the healthcare landscape, read insights from the Digital Therapeutics Alliance’s CEO.
Read Andy Molnar’s PDURS Thought Piece